Physical activity as a molecular modulator to enhance immunotherapy and drug sensitivity in the endometrial cancer–comorbidity continuum - Report - MDSpire
Advertisement
Physical activity as a molecular modulator to enhance immunotherapy and drug sensitivity in the endometrial cancer–comorbidity continuum
Clinical Report: The Role of Physical Activity in Endometrial Cancer Treatment
Overview
This review explores the role of physical activity in endometrial cancer (EC) patients with comorbid conditions. It highlights the molecular mechanisms through which exercise may modulate the tumor microenvironment.
Background
Endometrial cancer is the most common gynecologic malignancy, often complicated by comorbidities such as hypertension and chronic kidney disease, which can hinder effective treatment. The systemic inflammatory burden and uremic toxins associated with these conditions can impair the efficacy of immunotherapies. Understanding the role of physical activity in this context is crucial for optimizing treatment strategies.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
Physical activity may act as a systems-level molecular modulator in endometrial cancer treatment.
Exercise can remodel the tumor microenvironment by repolarizing Tumor-Associated Macrophages and reducing Myeloid-Derived Suppressor Cells.
Enhanced cytotoxic T cell infiltration is associated with increased physical activity.
Exercise-induced shear stress promotes eNOS phosphorylation, which may normalize tumor vasculature.
Personalized exercise prescriptions may serve as a non-pharmacological adjuvant in EC patients.
Clinical Implications
Incorporating physical activity into treatment plans for endometrial cancer patients with comorbidities may be beneficial.
Conclusion
Physical activity presents a promising adjunctive strategy in the management of endometrial cancer, particularly for patients facing therapeutic challenges due to comorbidities.
